Optimising delivery systems for HRT

Maturitas

Volumn 33, Issue SUPPL. 1, 1999, Pages 31-38

  Stevenson, J C ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

HRT; Oral; Tolerability.; Transdermal

Indexed keywords

CONJUGATED ESTROGEN; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; MEDROGESTONE; NOMEGESTROL ACETATE; NORGESTREL; PROGESTERONE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; GEL; HORMONE SUBSTITUTION; HUMAN; IMPLANT; INTRAVAGINAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POSTMENOPAUSE; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; PROGESTINS;

EID: 0032752740     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(99)00061-4     Document Type: Article

References (19)

1. Okon MA, Lee S, Li TC. A study to examine women's knowledge, perception and acceptability of hormone replacement therapy. Eur Menopause J 1996;3(2):47-52.
2. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992;15:151-8.
3. Campagnoli C, Lesca L, Cantamessa C, Peris C. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings. Maturitas 1993;18:21-46.
4. Lievertz R. Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol 1987;156(51):1289-93.
5. Crook D, Stevenson JC. Transdermal hormone replacement therapy, serum lipids and lipoproteins, Brit. J. Clin. Pract. 1996;(Suppl. 86):17-21
6. Sullivan JM. Practical aspects of preventing and managing atherosclerotic disease in post-menopausal women. Eur Heart J 1996;17(Suppl. D):32-7.
7. Rozenbaum H, Birkhaüser M, De Nooyer C. Comparison of two estradiol transdermal systems (OESCLIM® 50, ESTRADERM TTS® 50) I. Tolerability, adhesion and efficacy. Maturitas 1996;25:161-73.
8. Cooper C, Stakkestad A, Radowicki S, et al. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. Osteoporos Int 1999;9:358-66.
9. Gambacciani M, Cappagli B, Piaggesi L, Spinetti A, Ciaponi M, Genazzani AR. Effects of transdermal estradiol administration on bone mass and bone metabolism in early postmenopausal women. Eur Menopause J 1996;3(1):7-12.
10. Hillard TC, Whitcroft SIJ, Marsh MS, Ellerington MC, Lees B, Whitehead MI, Stevenson JC. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis Int 1994;4:341-8.
11. Foidart JM. Use of transdermal oestradiol (Estraderm TTS) in hypertensive postmenopausal women, Brit. J. Clin. Prac. 1996;(Suppl. 86):14-16
12. Crook D, Cust MP, Gangar KF. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950-5.
13. Pang SC, Lozano K, Greendale GA. Long-term effects of transdermally administered estradiol with or without medroxyprogesterone acetate. Fertil Steril 1993;59:76-82.
14. Whitcroft SI, Crook D, Marsh MS, Ellerington MC, Whitehead MI, Stevenson JC. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol 1994;84:222-6.
15. Utian WH, Burry KA, Archer DF, Gallagher JC. The Esclim® Study Group et al. Efficacy and safety of low, standard and high dosages of an estradiol transdermal system (Esclim®) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am J Obstet Gynecol 1999;181(1):71-9.
16. Rozenbaum H, Birkhaüser M, De Nooyer C. Comparison of two estradiol transdermal systems (OESCLIM® 50, ESTRADERM TTS® 50) II. Local skin tolerability. Maturitas 1996;25:175-85.
17. Guy M. OESCLIM®: Pre-clinical and clinical profile. Maturitas. 1999;33(Suppl. 1):S49-S55.
18. Chetkowski RJ, Meldrum DR, Steingold KA. Biological effects of transdermal estradiol. N Engl J Med 1986;314:1615-20.
19. Thacker H. Update on hormone replacement: sorting out the options for preventing coronary artery disease and osteoporosis. Medscape Women's Health. 1996;1(6).